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1. INTRODUCTION
 2 
1.1. Diabetes 
 
Dr. Margaret Chan, former Director-General of the World Health Organization (WHO), 
addresses the global issue of the chronic disease diabetes, in the current Global Report on 
Diabetes, released in 2016 by the WHO, with the following words: “Diabetes is on the rise. No 
longer a disease of predominantly rich nations, the prevalence of diabetes is steadily increasing 
everywhere, most markedly in the world’s middle-income countries. (…) Please join me in 
ensuring (…) that we may indeed halt the rise in diabetes.”(1). Diabetes and its associated 
diseases affect the everyday lives of millions of people worldwide.  
Diabetes mellitus (DM) is a chronic disease that occurs either due to the failure of the 
pancreas to produce sufficient quantities of the blood sugar regulating hormone insulin, or when 
the body is incapable of effectively using the insulin it produces. This disease is such an 
important public health issue, that it belongs to one of four priority noncommunicable diseases 
targeted for action by world leaders (2).  
The International Diabetes Federation estimated that diabetes will cause 4 million 
deaths worldwide in 2017 of people aged between 20 and 79. This would be the equivalent to 
one death every 8 seconds and would make up a total of 10.7% of the global all-cause mortality 
among people in the previously defined age group. The latest release of the Diabetes Atlas, by 
the International Diabetes Federation, approximated that 451 million people worldwide, over 
the age of 18 years, were affected by diabetes in 2017 (3). Numbers have been increasing 
steadily over the past 3 decades, as well as associated risk factors such as obesity and 
overweight, which are also on the rise (4). These millions of people are not only suffering from 
the consequences of diabetes itself but are at a high risk for associated diseases. Today we know 
that diabetes is an important cause of blindness, kidney failure, as well as lower limb 
amputation, and other long-them consequences that have a significant impact on the quality of 
life (5).  
The term “triopathy” has been established since the 1950s and appeared in the paper 
Triopathy of Diabetes. The term "triopathy" has been applied to patients with diabetes, who 
have shown first clinical evidence of neuropathy, then diabetic retinopathy, and finally the 
nephropathy of diabetes (6). Since then the effort in understanding, diagnosing, and treating the 
disease itself, as well as its “triopathy” has been of great interest to the medical community and 
the general population. 
The purpose of this thesis therefore was to examine and statistically analyze the 
correlation of diabetic retinopathy and diabetic neuropathy. Therefore, we selected a well-
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defined group of 29 patients, with type 2 diabetes mellitus, in the population of Dalmatia and 
tried to establish a correlation between those two well defined complications of diabetes. 
 
1.2. Anatomy and Physiologic Anatomy of the Human Pancreas 
 
The pancreas lies mostly posterior to the stomach and extends across the posterior 
abdominal wall from the duodenum, on the right, to the spleen, on the left. The pancreas 
consists of the uncinate process, head, neck, body, and tail, and lies secondarily 
retroperitoneally, except for a small part of its tail. The pancreatic duct begins in the tail of the 
pancreas and joins the bile duct in the head of the pancreas and form the hepatopancreatic 
ampulla (ampulla of Vater). The arterial supply of the pancreas includes the gastroduodenal 
artery, superior and inferior pancreaticoduodenal arteries, and dorsal pancreatic artery (7).  
The pancreas is a large compound gland and is composed of two major types of tissues: 
the acini, which secrete digestive juices, and islets of Langerhans, which secrete insulin and 
glucagon directly into the blood (8). The acini secrete digestive enzymes, for digesting all three 
major types of food (proteins, carbohydrates, fats) and large volumes of sodium bicarbonate, 
which aid in neutralizing the acidity of chyme, that empty directly into the duodenum through 
the papilla of Vater (8). Furthermore, the pancreas secretes hormones such as somatostatin, 
amylin, and pancreatic polypeptide (8). These hormones will not be described any further in 
this thesis, since the main purpose of this section is to focus on the physiological roles of two 
other pancreatic hormones, insulin and glucagon, to later on elaborate on the pathophysiology 
of the disease diabetes mellitus (8). 
In addition to its digestive functions, the human pancreas contains 1 to 2 million islets 
of Langerhans, organized around small capillaries into which its cells directly secrete their 
hormones into the blood circulation (8). The physiologic anatomy of the islets of Langerhans 
are being presented in Figure 1. These islets are made up of three major cell types: alpha 
(approximately make up 25% of all cells of the islets), beta (60%), and delta cells (10%) (8). 
Each type of cells is differentiated by its morphological and staining characteristics (8). Further 
alpha cells are responsible for the secretion of the hormone glucagon, beta cells secrete insulin 
and amylin, and delta cells secrete somatostatin. The two afore mentioned hormones, insulin 
and glucagon, that are necessary for the appropriate regulation of glucose, lipid, and protein 
metabolism, will be the main focus of the following section (8). 
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Figure 1. Physiologic anatomy of an islet of Langerhans in the pancreas (8). 
 
1.3. Insulin  
  
Insulin is a hormone associated with energy abundance. When there is an increased 
availability of energy-giving foods in the diet, especially high amounts of carbohydrates, insulin 
secretion increases in response. This consequently plays an important role in storing this excess 
energy in specific tissues. Excess carbohydrates are stored mainly in the liver and muscles as 
glycogen. In a state, in which carbohydrates are available in concentrations too high that they 
cannot be stored as glycogen, they are converted to fats and stored in adipose tissue under the 
direct stimulus of insulin. Insulin further plays a key role in protein metabolism, by having a 
direct effect in promoting amino acid uptake by cells and their consequent conversion into 
proteins. Furthermore, it inhibits the breakdown of proteins that are already available within 
the cells (8). 
 Human insulin is a small protein that has a molecular weight of 5808, is composed of 
two amino acid chains that are connected by disulfide linkages. It is synthesized in the 
pancreatic beta cells, beginning with translation of the insulin ribonucleic acid (RNA) by 
ribosomes attached to the endoplasmic reticulum to form preproinsulin, which is then cleaved 
in the endoplasmic reticulum to form proinsulin. The majority of the proinsulin is further 
cleaved in the Golgi apparatus to form insulin (8). 
 After insulin has been secreted into the blood via secretory granules, it has a plasma 
halflife of approximately 6 minutes and is mainly cleared from the circulation within 10 to 15 
minutes, mostly by the enzyme insulinase in the liver and to a lesser extent in the kidneys and 
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muscles and slyghtly by most other tissues. This rapid removal from the plasma is important to 
rapidly turn off or turn on the control functions of insulin (8).  
 For the hormone to initiate its effects on target cells, it has to first bind with and activate 
a specific membrane receptor protein. This activated membrane receptor is then responsible for 
the subsequent effects. The insulin receptor, representing an enzyme-linked receptor,  is made 
up of four subunits, two alpha and two beta subunits, that penetrate the cell membrane and 
protruding into the cytoplasm. Insulin then binds to the extracellular alpha subunits causing the 
beta subunits protruding into the cell to be autophosphorylated. Autophosphorylation activates 
a local tyrosine kinase, which further phosphorylates multiple other inreacellular enzymes 
including a group of insulin-receptor enzymes (IRS). These IRS are expressed in different types 
of tissues throughout the body and the net effect is to activate and inactivate some of these 
enzymes. By this mechanism, insulin directs the intracellular metabolic machinery to cause the 
desired effects on carbohydrate, fat, and protein metabolism (8).  
The outcome and end-effects of insulin stimulation are summarized as following:  
1. Within seconds after the activation of insulin receptors, approximately 80% of the 
body’s cell’s membranes increase their uptake of glucose, especially in muscle and 
adipose tissue, which is immediately transported into the cells and phosphorylated, and 
becomes a substrate for all the usual carbohydrate metabolic functions (8). 
2. The cell’s membrane permeability increases towards amino acids, potassium ions, and 
phosphate ions, causing an increased influx of these substances into the cell (8). 
3. Within the next 10 to 15 minutes, activity levels of many intracellular metabolic 
enzymes change, as a result of phosphorylation of the enzymes (8). 
4. After hours to several days slower effects continue to be seen. These result from changes 
in rates of translation of messenger RNA (mRNA) at the ribosomes to form new proteins 
and changed rates of transcription of deoxyribonucleic acid (DNA) in the cell nucleus. 
Thus, insulin remolds the cellular enzymatic machinery to achieve its metabolic goals 
(8). 
 
1.4. Diabetes Mellitus 
 
The syndrome of diabetes mellitus is comprised of impaired carbohydrate, fat, and 
protein metabolism caused by either lack of insulin secretion or a decreased sensitivity of the 
tissues to the hormone. It is defined as a fasting plasma glucose level of greater than or equal 
to 7.0 mmol/L or on medication for diabetes a raised blood glucose value (1). Diabetes mellitus 
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is categorized into two general types. Firstly, type 1 diabetes mellitus, which is caused by a lack 
of insulin secretion. Secondly, type 2 diabetes mellitus, that is caused by a decreased sensitivity 
of target tissues to the metabolic effect of insulin. Often this reduction in sensitivity to insulin 
is called insulin resistance. In both type 1 diabetes mellitus and type 2 diabetes mellitus we can 
find a change in metabolism of all the main foodstuff. The basic outcome of this insufficiency, 
either due to lack or resistance, on glucose metabolism is the prevention of efficient uptake and 
utilization of glucose by most cells of the body. Thus, glucose concentration increases, cell 
utilization of glucose decreases progressively, and utilization of fats and proteins increase (8). 
 
1.5. Type 2 Diabetes Mellitus   
 
Approximately 90 to 95 percent of all cases of diabetes mellitus is due to type 2 diabetes 
mellitus (8). The usual age of onset, for type 2 DM, occurs after the age of 30 and often 
commences between the ages of 50 to 60 years of age. Therefore the syndrome has been also 
referred to as adult-onset diabetes (8). In the past, mainly middle-aged and elderly people were 
affected, but within recent years, type 2 DM occurs increasingly frequently in children and 
young people (1). This trend appears to be caused by a marked increase in the prevalence of 
obesity in this vulnerable population and is the main risk factor for type 2 DM (8). 
 Type 2 DM is associated with hyperinsulinemia, hence. This results out of a 
compensatory response, by the beta cells of the pancreas, for diminished sensitivity of the target 
tissue to insulin. This diminished responsiveness to the hormones’ metabolic effects is also 
referred to as insulin resistance. This insulin resistance consequently impairs carbohydrate 
utilization and storage, thus raising blood glucose levels and stimulating a compensatory 
increase in insulin secretion (8).  
 Currently the diagnosis of type 2 DM is based on glucose tolerance, which is classified 
into three broad categories: normal glucose homeostasis, diabetes mellitus and impaired 
glucose homeostasis. The glucose tolerance can be assessed using the fasting plasma glucose 
(FPG), oral glucose challenge, or the hemoglobin A1C (A1C). An FPG of less than 5.6 mmol/L, 
a plasma glucose of less than 11.1 mmol/L after an oral glucose challenge, and an A1C of less 
than 5.6% are considered to define normal glucose tolerance. Further, the International Expert 
Committee has issued diagnostic criteria for diabetes mellitus based on the following items: the 
FPG, the response to an oral glucose challenge, and A1C differ among individuals, and DM is 
defined as the level of glycemia at which diabetes-specific complications occur, rather than on 
deviations from a population based mean (9). 
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 These diabetes-specific chronic complications affect a great range of organ systems and 
are responsible for the majority of morbidity and mortality associated with the disease. These 
chronic complications can be divided into vascular and non-vascular complications. Vascular 
complications can further be subdivided into microvascular complications, such as retinopathy, 
neuropathy, as well as nephropathy, and macrovascular complications, for example coronary 
heart disease, cerebrovascular disease, or peripheral arterial disease (9).  
 
1.6. Anatomy of the Human Eye  
  
The human eye is a globe-shaped organ, occupying the anterior part of the orbit. The 
eyeball in its rounded shape is disrupted anteriorly by the transparent cornea, which bulges 
outward, and represents about one-sixth of the total eye surface. Going in order from front to 
back, posterior to the cornea, we can find the anterior chamber, iris, pupil, the posterior 
chamber, lens, the postremal (vitreous) chamber, the retina, and the choroid (7) as seen in Figure 
2. 
 
Figure 2. Cross sectional view of the human eyeball (7).  
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The part of interest, to this thesis, is the inner layer of the eyeball, the retina. The retina 
consists of two parts, the optic part of the retina and nonvisual part. The optic part takes up the 
posterior and lateral aspects of the retina and is sensitive to light. Further, the optic part of the 
retina consists of two layers, an inner neural and an outer pigmented layer. In contrast the 
nonvisual part is limited to the anterior surface and covers the internal surface of the ciliary 
body and the iris. These two parts are being divided at their junction by an irregular line called 
the ora serrata (7). 
 Several other features can be noted on the posterior surface of the optic part of the retina. 
The optic disc is an area which is lighter than the surrounding retina and is the location where 
the optic nerve leaves the retina. It is also the location at which branches of the central retinal 
artery spread from outward, to supply the retina. Since there is no light sensitive tissue in this 
area, it is also being referred to as the so-called blind spot in the retina. Beyond that, we can 
find another structure lateral to the optic disc. This small yellowish colored area is the macula 
lutea with its central depression, called the fovea centralis. Here we find the thinnest area of the 
retina which stands out in its high visual sensitivity relative to the surrounding tissue. This is 
due to decreased number in rods, the light-sensitive receptor cells that function in dim light and 
are not sensitive to color, and higher concentration of cones, the counterpart, which are light-
sensitive receptor cells that respond to bright light and are sensitive to color (7).  
 
1.7. Diabetic Retinopathy 
 
 The short definition of diabetic retinopathy is, that diabetic retinopathy is a 
neurovascular disease. This neurovascular disease is one of the main causes of acquired 
blindness at the age of 30 to 60 years of age in industrialized countries and approximately 90% 
of patients with DM will have retinopathy after 20 years. Further, 90% of all visual impairments 
in diabetic patients are caused by diabetic retinopathy and the overall prevalence accounts for 
7% in industrialized countries (10).  
 As previously mentioned, diabetic retinopathy is a microvascular complication or in 
more specific terms, a microangiopathy (10). Hyperglycemia is considered to play an essential 
part in the pathogenesis of retinal microvascular damage. Numerous metabolic pathways have 
been suspected in hyperglycemia-induced vascular damage. These include the polyol pathway, 
advanced glycation end products accumulation, protein kinase C pathway, and the hexosamine 
pathway (11).  
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This microangiopathy ultimately leads to the thickening of the basement membrane of 
the vessels and a loss in pericytes and vascular endothelial cells. As afore mentioned, 
hyperglycemia, as described in patients with DM, plays a key role at its early stage. Later and 
due to the prolonged injury to the vessels, capillary closure occurs, which eventually leads to a 
hypoxic environment and consequently to retinal ischemia. In the ischemic retina angiogenic 
factors are produced, such as vascular endothelial growth factor and insulin-like growth factor-
1. These contribute to new vessel formation in the pre-retinal area and iris. If at any stage, the 
blood-retina barrier breaks down and an increased vascular permeability occurs, macular edema 
may develop (10).  
During the progression of diabetic retinopathy, retinal neurodegeneration can be 
observed as an early event. Animal studies involving diabetic rats have shown, that apoptosis 
of retinal neurons can be observed as early as one month after induction of diabetes. 
Upregulation of pro-apoptotic molecules such as Fas, Bax, and cleaved caspase-3 was detected 
in retinal neurons of both diabetic animals and human subjects. Further mitochondrial 
dysfunction has been implicated in diabetic retinopathy’s retinal degeneration. Currently there 
is growing evidence that retinal neurodegeneration could be a separate pathophysiology of 
diabetic retinopathy (11).  
 Presently the most common international nomenclature used to describe the various 
changes seen in the patient with diabetic retinopathy, is based on the classification of the 
Diabetic retinopathy Study. The classification relies on the distinction between non-
proliferative and proliferative stages with the characteristics of mild, moderate, and high risk, 
as well as clinically significant macular edema and ischemic maculopathy (10). The following 
Table 1 is a gives a comprehensive overview of the Diabetic Retinopathy Disease Severity 
Scale and International Clinical Diabetic Retinopathy Disease Severity Scale (12). 
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Table 1. Diabetic Retinopathy Disease Severity Scale and International Clinical Diabetic 
Retinopathy Disease Severity Scale (12). 
Disease Severity Level Findings upon Dilated Ophthalmoscopy 
 No apparent retinopathy  
Mild NPDR (see Glossary) 
Moderate NPDR 
 
Severe NPDR (International Definition) 
 
 
 
 
 
 
 
 
PDR (see Glossary) 
No abnormalities 
Microaneurysms only  
More than just microaneurysms but less than severe 
NPDR 
Anything of the following and no signs of 
proliferative retinopathy: 
• More than 20 intraretinal hemorrhages in 
each of four retinal quadrants 
• Definite venous beading in two or more 
quadrants  
• Prominent IRMA (see Glossary) in one or 
more quadrants  
One or both of the following  
• Neovascularization 
• Vitreous/preretinal hemorrhage 
IRMA = intraretinal microvascular abnormalities; NPDR = non-proliferative diabetic 
retinopathy; PDR = proliferative diabetic retinopathy  
Note:  
• Any patient with two or more of the characteristics of severe NPDR is considered to 
have very severe NPDR.  
• PDR may be classified as high-risk and non-high-risk. 
 
Symptoms of diabetic retinopathy appear late throughout the course of disease. Therefore, 
only in the late stages and with macular involvement or vitreous hemorrhage will the affected 
individual notice visual impairment or even sudden blindness (10). 
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1.8. Physiologic Anatomy of the Human Nervous System 
 
 The human nervous system is formed by a network of many billion nerve cells, also 
called neurons, and forms by far the most complex system in the body. Further, all neurons are 
being supported by many cells called glial cells. Through a complex network of neurons, in 
which every neuron interconnects a hundredfold to other neurons, they form a very complex 
system for processing information and generating responses. The nervous system (NS) and its 
distribution throughout the body forms an integrated communications network. Viewed from 
an anatomical angle, the general organization of the NS has two main divisions. First, the 
central nervous system (CNS), consisting of the brain and spinal cord, and the peripheral 
nervous system (PNS), composed of the cranial, spinal, and peripheral nerves. Therefore, the 
PNS is responsible for conducting impulses to and from the CNS (respectively sensory and 
motor nerves) and ganglia (small aggregates of nerve cells outside the CNS) (13). 
 Neurons possess the capability to respond to environmental changes, also referred to as 
stimuli, by changing the ionic gradient that exists across their cell membranes. This gradient, 
also called an electrical potential, is universal to all cells. Only cells that can rapidly change 
this potential in response to a stimulus are said to be excitable. Neurons can instantly react to 
such stimuli through the reversal of the ionic gradient or in other terms via membrane 
depolarization. This depolarization usually spreads from the place of reception across the 
neuron’s entire plasma membrane. This propagation called the action potential (AP) is capable 
of propagating long distances along neuronal processes. By this mechanism such signals are 
stimulating other neurons, muscles or even glands. Through collecting, analyzing, and 
integrating information as AP, the NS continuously stabilizes the intrinsic homeostasis of the 
organism within normal ranges and maintains behavioral patterns (13).    
 
1.9. Diabetic Neuropathy  
 
 Diabetic neuropathies are the most common chronic complications of diabetes and are 
defined as “signs and symptoms of peripheral nerve dysfunction in a patient with diabetes 
mellitus in whom other causes of peripheral nerve dysfunction have been excluded” ((14)(15). 
Further, diabetic neuropathy is one of the most common causes of peripheral neuropathy and 
accounts for more frequent hospitalizations than any other complication of diabetes mellitus 
and above that it poses the most frequent indication for non-traumatic amputation (14).     
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 The etiology of diabetic neuropathy remains unknown up to date, but experimental 
studies suggest a multifactorial pathogenesis, with ischemic and metabolic components 
implicated. A prevailing view of the pathogenesis is that inflammatory and oxidative stress 
may, in the context of metabolic dysfunction, damage nervous tissue (15).  
Hyperglycemia is thought to play an essential part in the pathogenesis of the disease by 
inducing rheological changes. These changes increase the endothelial vascular resistance and 
thereby reduce blood flow to the nerve. Further hyperglycemia also causes depletion of the 
nerve’s myoinositol, a glucose derivative, via a competitive uptake mechanism. The activation 
of the polyol pathway in the nerve leads to an accumulation of sorbitol and fructose in the tissue, 
thus inducing a non-enzymatic glycosylation of structural nerve proteins. Hyperglycemia also 
causes oxidative stress and activation of protein kinase C, which was linked to vascular damage 
in diabetic neuropathy. Through direct measurement of glucose, sorbitol, and fructose, in 
nervous tissue of patients with DM, a correlation with the severity of neuropathy could be 
established. All these changes lead to an abnormal neuronal, axonal, and Schwann cell 
metabolism, which ultimately cause an impaired axonal transport (14). A comprehensive 
overview of the involved mechanisms of diabetic neuropathy can be seen in the following 
Figure 3. 
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ER = endoplasmic reticulum; FFA = free fatty acids; PI3-K = phosphatidylinositol-3 kinase; 
RNS = reactive nitrogen species; ROS = reactive oxygen species 
Note: 
• Factors linked to type 1 diabetes (yellow), type 2 diabetes mellitus (blue), and both 
(green) cause DNA damage, endoplasmic reticulum stress, mitochondrial dysfunction, 
cellular injury, and irreversible damage.  
• The relative importance of the pathways in this network will vary with cell type, disease 
profile, and time. 
Figure 3. Mechanisms of diabetic neuropathy (15). 
 
Until today, diabetic neuropathy is a diagnosis of exclusion and the most common forms 
encountered in practice are distal symmetric polyneuropathy and autonomic neuropathy. This 
heterogeneous group of conditions can affect different parts of the nervous system and may 
presents as a diverse clinical picture. The following Table 2 provides a comprehensive 
classification scheme, based on the position paper by the American Diabetes Association from 
2017, for the diabetic neuropathies. 
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Table 2. Classification for diabetic neuropathies from Diabetic Neuropathy: A Position 
Statement by the American Diabetes Association 
Diabetic neuropathies 
A. Diffuse neuropathy 
Distal Symmetric Polyneuropathy 
Primarily small-fiber neuropathy 
Primarily large-fiber neuropathy 
Mixed small- and large-fiber neuropathy (most common) 
Autonomic 
Cardiovascular 
Reduced HRV 
Resting tachycardia 
Orthostatic hypotension 
Sudden death (malignant arrhythmia) 
Gastrointestinal 
Diabetic gastroparesis (gastropathy) 
Diabetic enteropathy (diarrhea) 
Colonic hypomotility (constipation) 
Urogenital 
Diabetic cystopathy (neurogenic bladder)  
Erectile dysfunction 
Female sexual dysfunction 
Sudomotor dysfunction 
Distal hypohydrosis/anhidrosis, 
Gustatory sweating 
Hypoglycemia unawareness 
Abnormal pupillary function 
B. Mononeuropathy (mononeuritis multiplex) (atypical forms) 
Isolated cranial or peripheral nerve (e.g., cranial nerve III, ulnar, median,  
femoral, peroneal) 
Mononeuritis multiplex (if confluent may resemble polyneuropathy) 
C. Radiculopathy or polyradiculopathy (atypical forms) 
Radiculoplexus neuropathy (a.k.a. lumbosacral polyradiculopathy, proximal  
motor amyotrophy) 
Thoracic radiculopathy 
Nondiabetic neuropathies common in diabetes 
Pressure palsies 
Chronic inflammatory demyelinating polyneuropathy 
Radiculoplexus neuropathy 
Acute painful small-fiber neuropathies (treatment-induced) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. OBJECTIVES
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The objective of this study was to provide a comprehensive insight into common 
pathological mechanisms of diabetic retinopathy and neuropathy. Thus, we aimed at studying 
patients with long-standing type 2 diabetes mellitus who were prone to have detectable and 
gradable diabetic retinopathy and evaluate a possible association with sensitive measures of 
diabetic neuropathy. 
 
Hypothesis 
 
1. There is no correlation between diabetic retinopathy and diabetic neuropathy. 
2. There is no correlation between diabetic retinopathy and age. 
3. There is a no correlation between diabetic retinopathy and duration of insulin therapy. 
4. There is no correlation between diabetic retinopathy and duration of type 2 diabetes 
mellitus. 
5. There is no correlation between diabetic sensory-motor neuropathy and age. 
6. There is a no correlation between diabetic sensory-motor neuropathy and duration of 
insulin therapy. 
7. There is no correlation between diabetic sensory-motor neuropathy and duration of type 
2 diabetes mellitus. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. MATERIALS AND METHODS
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3.1. Study Design 
 
This study was conducted at the Department of Ophthalmology and at the Department 
of Neurology of the University Hospital of Split. It was carried out in adherence to the tenets 
of the Declaration of Helsinki and Good Clinical Practice guidelines. According to the 
population-based design, this is a cohort study. The ethical approval for this study was obtained 
by the University of Split School of Medicine. 
 
3.2. Subjects 
 
 The population-based cohort study included patients from the Split-Dalmatia county, 
creating a total sample size of twenty-nine examinees. Twenty-nine adult patients with type 2 
diabetes mellitus, 11 female and 18 male patients, with a diagnosis of more or equal to 1 year 
were included into the study. Of those patients that were screened, 1 patient presented with no 
diabetic retinopathy or features of other ocular pathologies, such as non-proliferative diabetic 
retinopathy or macular edema. 
 
3.3. Materials and Methods 
  
After written informed consent was obtained of all examinees, all participants 
underwent a detailed screening for medical history, duration of type 2 diabetes mellitus 
diagnosis, duration of insulin therapy, grade of diabetic retinopathy and clinically significant 
macular edema, using the Diabetic Retinopathy Disease Severity Scale and International 
Clinical Diabetic Retinopathy Disease Severity Scale and a detailed ophthalmologic 
examination according to the protocol, as well as sensory-motor neuropathy and radiculopathy, 
using electromyographic studies with the Medelec Synergy 5 Channel EMG/EP Plinth System 
(Oxford Instruments Medical Ltd, U.K., 2004). 
 
3.3.1. Grading of Diabetic Retinopathy and Clinically Significant Macular Edema  
 
For the grading of diabetic retinopathy and clinically significant macular edema the 
Diabetic Retinopathy Disease Severity Scale and International Clinical Diabetic Retinopathy 
Disease Severity Scale were used as introduced by the Early Treatment of Diabetic Retinopathy 
Study (ETDRS). Diabetic retinopathy was classified as absent, mild, moderate, severe, or 
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proliferative in accordance to the criteria established in the Early Treatment Diabetic 
Retinopathy Study. This was achieved by comparing stereophotographs in seven standard color 
fundus photographic fields, with the examinees findings in those same seven defined fields 
(16).  
Further, as introduced by the EDTRS, clinically significant macular edema (CSME) was 
defined upon slit lamp biomicroscopy as “(1) thickening of the retina at or within 500 µm of 
the center of the macula; or (2) hard exudate at or within 500 µm of the center of the macula 
associated with thickening of adjacent retina; or (3) a zone of retinal thickening 1 disc area or 
larger, any part of which is within 1 disc diameter of the center of the macula” (16). 
 
3.3.2. Grading of Sensory-Motor Neuropathy and Radiculopathy 
 
 The diagnosis of diabetic neuropathy is principally a clinical one (15). In the evaluation 
of  patients with neuropathy or nerve injury, it is important to assess the physiologic status of 
peripheral nerves with nerve conduction studies, such as electromyography, in order to assess 
and correlate their physiological status with their clinical symptoms (17). Therefore, with the 
support of the Department of Neurology of the Medical University of Split, we developed a 
grading system based on the electromyographic examination of the common peroneal nerve. 
For that purpose, the conduction velocity of the common peroneal nerve was recorded and on 
the basis of those findings the grading system was formed. The grading comprised of four 
grades ranging from absent neuropathy to very sever neuropathy. The following Table 3 will 
provide a comprehensive overview of the grading system for diabetic neuropathy, developed 
by the Department of Neurology of the Medical University of Split for the purpose of this study.   
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Table 3. Grading System for Diabetic Neuropathy as Developed by the Department of 
Neurology of the Medical University of Split 
Grade  Description Conduction Velocity  
Grade 0  Without neuropathy >45 m/s 
Grade 1 Mild neuropathy 41-44 m/s 
Grade 2 Moderate neuropathy 35-40 m/s 
Grade 3 Severe neuropathy 30-34 m/s 
Grade 4 Very severe neuropathy <30 m/s 
 
 
3.4. Statistical Analysis 
 
Descriptive analysis included the presentation of data as absolute numbers and 
percentages for categorical and ordinal variables, further medians and interquartile range (IQR) 
were used in the case of a non-normal distribution of a numeric variable or a mean and standard 
deviation (SD) was used in the case of normally distributed numeric variable. The distribution 
of numeric variables was tested using a Kolmogorov-Smirnov test where non-parametric tests 
were used if we obtained a P <0.05 while parametric tests were used if P³0.05. Bivariate 
statistical analysis was performed using Spearman Rank correlation test (referred to as r) or 
Pearson’s correlation coefficient.  
The statistical analysis was performed, using the software STATISTICA 12 (TIBCO 
Software Inc. v12.0), and the P value significance threshold was set to <0.05. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. RESULTS
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4.1 Patient Characteristics 
A comprehensive and detailed description of the examined participants’ characteristics 
can be found in Table 2. 
 
 Table 2. Sociodemographic Characteristics of Participants  
 
Gender; n (%)  
  Male   18 (62.07) 
  Female  11 (37.93) 
Age (years); (mean ± SD)  62.34 ± 11.73 
Duration (years) of Type 2 DM Status; (mean ± SD) 15 ± 7.71 
Duration (years) of Insulin Therapy; n (median [IQR])) 16 (4 [3-10]) 
Grade of Diabetic Retinopathy; n (median [IQR]) 29 (2 [1-4]) 
Grade of Sensory-Motor Neuropathy; n (median [IQR]) 29 (2 [1-3]) 
Grade of Diabetic Retinopathy; n (%)  
  Grade 0 1 (3.45) 
  Grade 1 7 (24.14) 
  Grade 2 8 (27.59) 
  Grade 3 5 (17.24) 
  Grade 4 8 (27.59) 
Clinically Significant Macular Edema; n (%)  
  Yes 16 (55.17) 
  No 13 (44.83) 
More affected Eye by Diabetic Retinopathy; n (%)   
  Right  11 (37.93) 
  Left 11 (37.93) 
  Equal 7 (24.14) 
Grade of Sensory-Motor Neuropathy; n (%)  
  Grade 0 6 (20.69) 
  Grade 1   3 (10.34) 
  Grade 2 9 (31.03) 
  Grade 3 5 (17.24) 
  Grade 4 6 (20.69) 
Radiculopathy; n (%)  
  Yes 11 (37.93) 
  No 18 (62.07) 
SD = Standard Deviation; IQR = Interquartile  
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4.2 Diabetic Retinopathy and Sensory-Motor Neuropathy 
 
There was a significant strong positive correlation (r = 0.81) between sensory-motor 
neuropathy and diabetic retinopathy (P < 0.001). The following Figure 1 visualizes the 
correlation. 
 
Figure 1. Correlation between sensory-motor neuropathy and diabetic retinopathy 
 
 
Testing for the correlation between the grade of diabetic retinopathy and the age (years) 
of patients, we found a weak positive correlation (r = 0.21), which did not reach statistical 
significance (P = 0.26). Further, we found a negative, moderate (r = -0.57) correlation between 
the grade of diabetic retinopathy and duration of insulin therapy (years), that reached statistical 
significance (P = 0.02). The grade of diabetic retinopathy and duration of type 2 diabetes 
mellitus (years) patient status showed a very weak correlation (r = 0.0037) and no statistical 
significance (P = 0.98). A weak positive (r = 0.06) correlation between the grade of diabetic 
sensory-motor neuropathy and age (years), that did not reach statistical significance (P = 0.76), 
could be established. A significant negative moderate (r = -0.53) correlation was found between 
the grade of diabetic sensory-motor neuropathy and duration of insulin therapy (P = 0.035). 
Finally, there was no significant correlation between the grade of diabetic sensory-motor 
neuropathy and duration of disease (years) with type 2 diabetes mellitus (r = 0.08, P = 0.666).
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. DISCUSSION
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Diabetes is a global burden and awareness is on the rise. Nevertheless, there is a lack of 
knowledge about the disease itself and its severe complications (18). In 2010 diabetic 
retinopathy caused 1.9% of visual impairment and 2.6% of blindness globally (19). Meanwhile, 
studies suggest that the prevalence of any retinopathy in patients with diabetes is 35%, at the 
same time as proliferative retinopathy is 7% (20). Diabetic neuropathy still is a diagnosis of 
exclusion and there are currently no approved disease modifying therapies (15). The 
pathogenesis of both complications, diabetic retinopathy and diabetic sensory-motor 
neuropathy, is the same and therefore the occurrence of any one complication may indicate the 
presence or even reflect on the severity of disease in an affected person (18). If detected early 
on and treated appropriately, both these complications may be reversible up to a certain extent 
(18).  
To our knowledge, this is the first study to investigate correlations between the grade of 
diabetic retinopathy and the degree of sensory-motor neuropathy using objective diagnostic 
methods. Further we aimed at establishing further correlations between diabetic retinopathy 
and diabetic sensory-motor neuropathy to the patients’ age, duration of insulin therapy, as well 
as duration of type 2 diabetes mellitus disease status, in the area of the Split-Dalmatia county. 
Evaluation of the data yielded three main results. First, we were able to establish a significant 
and strong positive correlation between the grade of diabetic retinopathy and the grade of 
diabetic neuropathy. Further, we could show that there is a significant, moderate negative 
correlation between the grade of diabetic retinopathy and the duration of insulin therapy. 
Finally, we were able to prove that there is a significant, moderate negative correlation that 
applies to the grade of diabetic sensory-motor neuropathy and duration of insulin therapy. By 
establishing a significant and strong positive correlation between the grade of diabetic 
retinopathy and the grade of diabetic neuropathy, we may be able to develop future screening 
programs and therapy approaches that take both pathologies into account. We are aware that 
these findings are limited by the sample size as well as the lack in long term observation of the 
patients. Nonetheless, we should see this as an early approach and incentive to continue 
research in this field.  
The pathology and physiology of diabetic retinopathy and diabetic sensory-motor 
neuropathy have many triggering mechanisms in common. Hyperglycemia induces distinct 
metabolic pathways, such as the hexosamine pathway, activation of diacylglycerol and protein 
kinase C, non-enzymatic glycosylation polyol pathway, formation of advanced glycosylation 
end-products, and production of reactive oxygen species (21,22). Further, recent research has 
focused on the implications of chronic low-grade inflammation in the pathogenetic mechanisms 
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of diabetic retinopathy(23,24). Nevertheless, the complete mechanisms underlying neuronal 
degeneration in the retina is not yet fully comprehended, but elevated levels of glutamate, 
Müller cell activation, and the overexpression of the renin-angiotensin system by glial cells are 
currently reported to play an essential role (25–27). Although there is an extensive availability 
of diverse human and animal studies, mechanisms of possible associations between retinal 
neurodegeneration and vasculopathy remain unclear and require further research (28). Thus, 
understanding the underlying mechanisms of neurodegeneration is important for identifying 
new therapeutic targets and in the future prevention of advanced diabetic retinopathy (28). We 
hope that through the findings of this study future and further understanding of the 
pathophysiology of diabetic retinopathy and diabetic sensory-motor neuropathy and its 
relationship with diabetic systemic neuropathy may be facilitated. 
 In conclusion, this study should indicate timely and thorough ophthalmologic 
fundoscopic examination in diabetic patients presenting with clinical or subclinical sensory-
motor neuropathy. Further, retinal changes, that indicate diabetic retinopathy, should entail a 
more detailed interrogation of peripheral nerve symptoms and a more stringent diabetic control 
is recommended in hopes of delaying future retinopathy (28).
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. CONCLUSION
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This study investigated the correlation between the grade of diabetic retinopathy and the 
grade of diabetic neuropathy, which yielded the following main results. 
1. A significant and strong positive correlation between the grade of diabetic retinopathy 
and the grade of diabetic neuropathy could be established. 
2. A significant, moderate negative correlation between the grade of diabetic retinopathy 
and the duration of insulin therapy was observed. 
3. A significant, moderate negative correlation that applies to the grade of diabetic 
sensory-motor neuropathy and duration of insulin therapy was proven. 
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Objectives: The objective of this study was to provide a comprehensive insight into common 
pathological mechanisms of diabetic retinopathy and neuropathy. Thus, we aimed at studying 
patients with long-standing type 2 diabetes mellitus who were prone to have detectable and 
gradable diabetic retinopathy and evaluate a possible association with sensitive measures of 
diabetic neuropathy. 
 
Subjects and methods: The population-based cohort study included patients from the Split-
Dalmatia county, creating a total sample size of twenty-nine examinees. Twenty-nine adult 
patients with type 2 diabetes mellitus, 11 female and 18 male patients, with a diagnosis of more 
or equal to 1 year, were included into the study. All participants underwent a detailed screening 
for medical history, duration of type 2 diabetes mellitus diagnosis, duration of insulin therapy, 
grade of diabetic retinopathy and clinically significant macular edema, using the Diabetic 
Retinopathy Disease Severity Scale and International Clinical Diabetic Retinopathy Disease 
Severity Scale and a detailed ophthalmologic examination according to the protocol, as well as 
assessment of sensory-motor neuropathy and radiculopathy, using electromyographic studies 
with the Medelec Synergy 5 Channel EMG/EP Plinth System (Oxford Instruments Medical 
Ltd, U.K., 2004). 
 
Results: There was a significant strong positive correlation (r = 0.81) between sensory-motor 
neuropathy and diabetic retinopathy (p < 0.001). A negative, moderate (r = -0.57) correlation 
between the grade of diabetic retinopathy and duration of insulin therapy (years), that reached 
statistical significance (p = 0.02) could be established. A significant negative moderate (r = -
0.53) correlation was found between the grade of diabetic sensory-motor neuropathy and 
duration of insulin therapy (p = 0.035).  
 
Conclusions: We found a strong correlation between diabetic retinopathy and diabetic sensory-
motor neuropathy. Thus, patients presenting with diabetic retinopathy should be further 
questioned and investigated for diabetic sensory-motor neuropathy.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9. CROATIAN SUMMARY
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Naslov: Korelacija između dijabetičke retinopatije i motorno-senzorne neuropatije, kohortno 
istraživanje 
Ciljevi: Cilj ovog istraživanja je bio pružiti sveobuhvatan uvid u zajedničke patološke 
mehanizme dijabetičke retinopatije i neuropatije. Stoga smo proučavali pacijente s 
dugogodišnjim dijabetesom tipa 2 koji imaju dijabetičku retinopatiju i procijenili moguću 
povezanost sa senzibilnim pokazateljima dijabetičke neuropatije. 
Materijali i metode: Kohortno istraživanje uključivalo je bolesnike iz splitsko-dalmatinske 
županije, stvarajući ukupnu veličinu uzorka od 29 ispitanika.	U istraživanju je uključeno 29 
odraslih bolesnika s dijabetesom melitusom tipa 2 od kojih su 11 ženskog spola i 18 muškog 
spola, s dijagnozom više ili jednako 1 godine. Svi sudionici podvrgnuti su detaljnom pregledu 
povijesti bolesti, trajanja dijagnoze dijabetesa melitusa tipa 2, trajanja terapije inzulinom, 
stupnja dijabetičke retinopatije i klinički značajnog makularnog edema, uporabom Diabetic 
Retinopathy Disease Severity Scale i International Clinical Diabetic Retinopathy Disease 
Severity Scale, detaljnom oftalmološkom pregledu prema protokolu, kao i procjenu motorno-
senzorne neuropatije i radikulopatije, korištenjem elektromiografskih metoda s Medelec 
Synergy 5 Channel EMG/EP Plinth System (Oxford Instruments Medical Ltd, U.K., 2004). 
Rezultati: Postojala je značajna pozitivna korelacija (r = 0,81) između motorno-senzorne 
neuropatije i dijabetičke retinopatije (P <0,001). Može se utvrditi negativna, umjerena (r = -
0.57) korelacija između stupnja dijabetičke retinopatije i trajanja terapije inzulinom, koja je 
postigla statističku značajnost (P = 0.02). Značajna negativna umjerena (r = -0,53) korelacija 
pronađena je između stupnja dijabetičke motorno-senzorne neuropatije i trajanja terapije 
inzulinom (P = 0,035). 
Zaključci: Pronašli smo izraženu korelaciju između dijabetičke retinopatije i dijabetičke 
motorno-senzorne neuropatije. Stoga se pacijenti s dijabetičkom retinopatijom trebaju dodatno 
ispitivati i pregledati za dijabetičku motorno-senzornu neuropatiju.
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